RCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ESMO

HUTCHMED (China)Announcement

02/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251002:nRSB6653Ba&default-theme=true

RNS Number : 6653B  Hutchmed (China) Limited  02 October 2025

Press Release

 

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

 

 

Hong Kong, Shanghai & Florham Park, NJ - Thursday, October 2, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from
several studies of compounds discovered by HUTCHMED will be presented at the
European Society for Medical Oncology ("ESMO") Congress 2025, taking place on
October 17-21, 2025 in Berlin, Germany.

 

Results from the FRUSICA-2 registration study of the fruquintinib and
sintilimab combination as a second-line treatment for locally advanced or
metastatic renal cell carcinoma will be presented in a Mini Oral session.
Additionally, further analyses of the fruquintinib FRUSICA-1 study in
endometrial cancer and the savolitinib SACHI and SAVANNAH studies in non-small
cell lung cancer will be presented during the poster sessions.

 

Details of the presentations are as follows:

 

 Abstract title                                                                   Presenter / Lead author                      Presentation details
 SPONSORED STUDIES
 Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus    Zhenhua Liu                                  (https://meetings.asco.org/abstracts-presentations/246124) 2592MO
 (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic
(Chengdu, China)

 renal cell carcinoma (RCC): results from phase 3 part of a randomized,                                                        Mini Oral Session 1:
 open-label, active-controlled phase 2/3 study (FRUSICA-2)
GU tumours, renal & urothelial

                                                                                                                               Friday, Oct 17, 2025

                                                                                                                               Karlsruhe Auditorium - Hall 5.2

                                                                                                                               16:00 - 17:30 CEST
 A Fruquintinib Expanded Access Program (EAP) to Provide Treatment for            Stefan Kasper-Virchow                        794P
 Patients With Metastatic Colorectal Cancer (mCRC)
(Essen, Germany)

                                                                                                                               Poster Session:

Colorectal cancer
 Fruquintinib plus tislelizumab in microsatellite stable metastatic colorectal    N. Arvind Dasari                             799P
 cancer: Results from a phase 1b/2 study
(Houston, USA)

                                                                                                                               Poster Session:

Colorectal cancer
 A novel artificial intelligence (AI) imaging biomarker of tumor vascularity      Sara Lonardi                                 804P
 and heterogeneity radiomics to predict survival benefit of fruquintinib vs
(Padua, Italy)

 placebo in metastatic colorectal cancer (mCRC)                                                                                Poster Session:

Colorectal cancer
 Safety and tolerability of fruquintinib: Pooled analysis of three                Cathy Eng                                    811P
 placebo-controlled studies in patients with metastatic colorectal cancer
(Nashville, USA)

                                                                                                                               Poster Session:

Colorectal cancer
 Association between Metabolic Syndrome (MetS) and clinical outcomes of           Danbo Wang                                   1230eP
 Fruquintinib plus Sintilimab in Previously Treated Advanced Endometrial Cancer
(Shenyang, China)

 (EMC) Patients with pMMR Status: results from FRUSICA-1 study                                                                 Poster Session:

Gynaecological Cancer
 ctDNA analysis in phase 3 SACHI trial: savolitinib (savo) plus osimertinib       Yongfeng Yu                                  1954P
 (osi) versus chemotherapy (chemo) in MET-amplified (METamp) advanced NSCLC
(Shanghai, China)

 after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI)                                                        Poster Session:

NSCLC, metastatic
 SAVANNAH: Safety and tolerability of osimertinib (osi) + savolitinib (savo)      Quincy Siu-chung Chu                         1955P
 in EGFRm advanced NSCLC with MET overexpression and/or amplification
(Edmonton, Canada)

 (OverExp/Amp) following disease progression on osi                                                                            Poster Session:

NSCLC, metastatic
 MET testing and treatment (tx) sequencing after progression on first line        Julia Rotow                                  1956P
 (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and
(Boston, USA)

 acquired MET overexpression and/or amplification (OverExp/Amp): interim                                                       Poster Session:
 analysis of a global real world (rw) study
NSCLC, metastatic

 INVESTIGATOR-INITIATED STUDIES
 Fruquintinib plus sintilimab and SOX as conversion therapy for initially         Fei Ma                                       2159P
 unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC):
(Zhengzhou, China)

 Updated surgical and survival results from the single-arm, phase 2 clinical                                                   Poster Session: Oesophagogastric cancer
 trial
 Fruquintinib alternating with bevacizumab plus capecitabine as maintenance       Wangjun Liao                                 898eP
 therapy after first-line treatment in metastatic colorectal cancer (mCRC): A
(Guangzhou, China)

 multicenter, open-label, Phase II Study                                                                                       E-poster Session:

Colorectal cancer
 The efficacy and safety of surufatinib combined with chemotherapy in the         Qianqian Wang                                929P
 first-line treatment of advanced periampullary carcinoma: a single arm,
(Nanjing, China)

 prospective, exploratory clinical study                                                                                       Poster Session:

Developmental therapeutics
 Surufatinib-Based Late-Line Therapy Outcomes in Recurrent Metastatic NSCLC:      Yanfang Zheng                                1884P
 Monotherapy and Vinorelbine Combination Regimens
(Guangzhou, China)

                                                                                                                               Poster Session:

NSCLC, metastatic
 Surufatinib combined with Toripalimab, Pemetrexed, and Platinum in Advanced      Wenfeng Fang/ Li Zhang                       1887P
 Non-Squamous Non-Small Cell Lung Cancer (nsg-NSCLC): Final Phase ll Results
(Guangzhou, China)

 from a Single-Center Trial                                                                                                    Poster Session:

NSCLC, metastatic
 Efficacy/safety and preliminary scRNA-seq results of surufatinib plus            Song Gao/ Jihui Hao                          2236P
 gemcitabine and nab-paclitaxel as neoadjuvant therapy in resectable and
(Tianjin, China)

 borderline resectable pancreatic cancer                                                                                       Poster Session:

Pancreatic cancer
 Efficacy and Safety of Surufatinib in Patients with Advanced Soft Tissue         Xiaowei Zhang/ Zhiguo Luo (Shanghai, China)  2716P
 Sarcoma After Failure of Anthracycline Chemotherapy and Prior Effective

 Antiangiogenic Therapy: A Single-Arm, Prospective, Exploratory Phase II Study                                                 Poster Session:

Sarcoma

 

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three vascular endothelial
growth factor receptors ("VEGFR") -1, ‑2 and -3. Fruquintinib is
co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and
Company under the brand name ELUNATE(®). Takeda holds the exclusive worldwide
license to further develop, commercialize, and manufacture fruquintinib
outside mainland China, Hong Kong and Macau, marketing it under the brand name
FRUZAQLA(®).

 

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase
inhibitor that has demonstrated clinical activity in advanced solid tumors. It
blocks atypical activation of the MET receptor tyrosine kinase pathway that
occurs because of mutations (such as exon 14 skipping alterations or other
point mutations), gene amplification or protein overexpression.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and
commercialized by AstraZeneca under the brand name ORPATHYS(®).

 

About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively
inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast
growth factor receptor (FGFR), which both inhibit angiogenesis, and colony
stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated
macrophages, promoting the body's immune response against tumor cells.
Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA(®).
HUTCHMED currently retains all rights to surufatinib worldwide.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception it has
focused on bringing drug candidates from in-house discovery to patients around
the world, with its first three medicines marketed in China, the first of
which is also approved around the world including in the US, Europe and Japan.
For more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the US Private Securities Litigation Reform
Act of 1995. These forward-looking statements reflect HUTCHMED's current
expectations regarding future events, including but not limited to its
expectations regarding the therapeutic potential of fruquintinib, surufatinib
and savolitinib, the further clinical development for fruquintinib,
surufatinib and savolitinib, its expectations as to whether any studies on
fruquintinib, surufatinib and savolitinib would meet their primary or
secondary endpoints, and its expectations as to the timing of the completion
and the release of results from such studies. Such risks and uncertainties
include, among other things, assumptions regarding enrollment rates and the
timing and availability of subjects meeting a study's inclusion and exclusion
criteria; changes to clinical protocols or regulatory requirements; unexpected
adverse events or safety issues; the ability of fruquintinib, surufatinib and
savolitinib, including as combination therapies, to meet the primary or
secondary endpoint of a study, to obtain regulatory approval in different
jurisdictions and to gain commercial acceptance after obtaining regulatory
approval; the potential markets of fruquintinib, surufatinib and savolitinib
for a targeted indication, and the sufficiency of funding. In addition, as
certain studies rely on the use of other drug products such as sintilimab and
toripalimab as combination therapeutics, such risks and uncertainties include
assumptions regarding their safety, efficacy, supply and continued regulatory
approval. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see HUTCHMED's
filings with the US Securities and Exchange Commission, The Stock Exchange of
Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or
revise the information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be
available in all countries, or may be available under different trademarks,
for different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion or
advertisement for any prescription drugs including the ones under development.

 

CONTACTS
 Investor Enquiries                                  +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                    +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                     (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Alex Shaw                              +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                 +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                     (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                     Nominated Advisor and Joint Broker
 Atholl Tweedie / Emma Earl / Rupert Dearden         +44 20 7886 2500

 Cavendish                                           Joint Broker
 Geoff Nash / Nigel Birks                            +44 20 7220 0500

 Deutsche Numis                                      Joint Broker
 Freddie Barnfield / Jeffrey Wong / Duncan Monteith  +44 20 7260 1000

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABBBDGDUGDGUB